Clinical Trials Logo

Clinical Trial Summary

Sub Arachnoid Hemorrhage (SAH) is a public health concern because of its high incidence (7/100 000 inhab.), its mortality rate (25%), and its morbidity rate (50%).

Clinical Trial Description

Sub Arachnoid Hemorrhage (SAH) is a public health concern because of its high incidence (7/100 000 inhab.), its mortality rate (25%), and its morbidity rate (50%).

Prognostic tools are indispensable in guiding and optimizing the care of these patients.

Some diagnostic factors have been identified (e.g. age, comorbidities, ACSOS , GCS, ICP, occurrence of complications) as well as some classification schemes used for grading seriousness of the disease (Hunt and Hess, World Federation of NeuroSurgery).

A tool that is simple, reliable, reproducible, non costly, non invasive, and simple to perform (including remote methods and without changing planned patient care) would be ideal.

The measurement of the Optic Nerve Sheath Diameter (ONSD,) correlated by MRI and ultrasound in previous studies, with intra-cranial pressure (ICP: a fundamental prognostic factor for SAH) could be one of these tools.

This measurement, previously demonstrated using ultrasound, could be carried out at the time of the patient's initial cerebral scan.

In practice, at admission each patient undergoes a cerebral CT scan much more often than an ultrasound (faster, less costly, less technical training required).

Two preliminary studies seem to suggest that this measurement of ONSD on CTc is a predictive factor for morbi-morbidity in patients having serious traumatic skull fractures.The measurement is reliable, reproducible, non invasive, and non costly, with good sensitivity and specificity.

Proving that it is also applicable to SAH could be particularly useful. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02894034
Study type Observational
Source Centre Hospitalier Universitaire, Amiens
Status Active, not recruiting
Start date August 19, 2013
Completion date August 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Recruiting NCT02872857 - Subarachnoid Hemorrhage Recovery And Galantamine Phase 1/Phase 2
Completed NCT03164434 - Influence of Drainage on EVD ICP-signal N/A
Terminated NCT02216513 - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Phase 0
Active, not recruiting NCT02389634 - Identification of Novel Molecular Markers for Vasospasm N/A
Completed NCT01077206 - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage Phase 2/Phase 3
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Recruiting NCT00978822 - Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Recruiting NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH) N/A
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Completed NCT02483351 - Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome Phase 2/Phase 3
Recruiting NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT01447095 - Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage Phase 2
Completed NCT01024972 - Safety Study of Dantrolene in Subarachnoid Hemorrhage Phase 1/Phase 2
Completed NCT00823485 - Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture Phase 2/Phase 3
Recruiting NCT03249207 - SC IL-1Ra in SAH - Phase III Trial (SCIL) Phase 3
Recruiting NCT03496545 - Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury Phase 1/Phase 2